Translational Research
Volume 156, Issue 4 , Pages 216-225 , October 2010

“Venopathy” at work: recasting neointimal hyperplasia in a new light

Received 9 April 2010 ,Revised 5 July 2010 ,Accepted 13 July 2010.

References 

  1. U.S. Renal Data System. USRDS 2009 annual data report: atlas of chronic kidney disease and end-stage renal disease in the United States. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2009;
  2. Dember LM, Beck GJ, Allon M, et al. Effect of clopidogrel on early failure of arteriovenous fistulas for hemodialysis: a randomized controlled trial. JAMA. 2008;299:2164–2171
  3. Dixon BS, Beck GJ, Vazquez MA, et al. Effect of dipyridamole plus aspirin on hemodialysis graft patency. N Engl J Med. 2009;360:2191–2201
  4. Chang CJ, Ko PJ, Hsu LA, et al. Highly increased cell proliferation activity in the restenotic hemodialysis vascular access after percutaneous transluminal angioplasty: implication in prevention of restenosis. Am J Kidney Dis. 2004;43:74–84
  5. Roy-Chaudhury P, Kelly BS, Miller MA, et al. Venous neointimal hyperplasia in polytetrafluoroethylene dialysis grafts. Kidney Int. 2001;59:2325–2334
  6. Roy-Chaudhury P, Arend L, Zhang J, et al. Neointimal hyperplasia in early arteriovenous fistula failure. Am J Kidney Dis. 2007;50:782–790
  7. Li L, Terry CM, Shiu YT, Cheung AK. Neointimal hyperplasia associated with synthetic hemodialysis grafts. Kidney Int. 2008;74:1247–1261
  8. Roy-Chaudhury P, Sukhatme VP, Cheung AK. Hemodialysis vascular access dysfunction: a cellular and molecular viewpoint. J Am Soc Nephrol. 2006;17:1112–1127
  9. Pisoni RL. Vascular access use and outcomes: results from the DOPPS. Contrib Nephrol. 2002;137:13–19
  10. Rayner HC, Pisoni RL, Gillespie BW, et al. Creation, cannulation and survival of arteriovenous fistulae: data from the dialysis outcomes and practice patterns study. Kidney Int. 2003;63:323–330
  11. Roy-Chaudhury P, Spergel LM, Besarab A, Asif A, Ravani P. Biology of arteriovenous fistula failure. J Nephrol. 2007;20:150–163
  12. Mattsson EJ, Kohler TR, Vergel SM, Clowes AW. Increased blood flow induces regression of intimal hyperplasia. Arterioscler Thromb Vasc Biol. 1997;17:2245–2249
  13. Weiss MF, Scivittaro V, Anderson JM. Oxidative stress and increased expression of growth factors in lesions of failed hemodialysis access. Am J Kidney Dis. 2001;37:970–980
  14. Rectenwald JE, Moldawer LL, Huber TS, Seeger JM, Ozaki CK. Direct evidence for cytokine involvement in neointimal hyperplasia. Circulation. 2000;102:1697–1702
  15. Budu-Grajdeanu P, Schugart RC, Friedman A, Valentine C, Agarwal AK, Rovin BH. A mathematical model of venous neointimal hyperplasia formation. Theor Biol Med Model. 2008;5:2
  16. Allen KE, Varty K, Jones L, Sayers RD, Bell PR, London NJ. Human venous endothelium can promote intimal hyperplasia in a paracrine manner. J Vasc Surg. 1994;19:577–584
  17. Fukasawa M, Matsushita K, Kamiyama M, et al. The methylentetrahydrofolate reductase C677T point mutation is a risk factor for vascular access thrombosis in hemodialysis patients. Am J Kidney Dis. 2003;41:637–642
  18. Heine GH, Ulrich C, Sester U, Sester M, Kohler H, Girndt M. Transforming growth factor beta1 genotype polymorphisms determine AV fistula patency in hemodialysis patients. Kidney Int. 2003;64:1101–1107
  19. Lazo-Langner A, Knoll GA, Wells PS, Carson N, Rodger MA. The risk of dialysis access thrombosis is related to the transforming growth factor-beta1 production haplotype and is modified by polymorphisms in the plasminogen activator inhibitor-type 1 gene. Blood. 2006;108:4052–4058
  20. Lin CC, Yang WC, Lin SJ, et al. Length polymorphism in heme oxygenase-1 is associated with arteriovenous fistula patency in hemodialysis patients. Kidney Int. 2006;69:165–172
  21. Juncos JP, Tracz MJ, Croatt AJ, et al. Genetic deficiency of heme oxygenase-1 impairs functionality and form of an arteriovenous fistula in the mouse. Kidney Int. 2008;74:47–51
  22. Lin CC, Chang CF, Lai MY, Chen TW, Lee PC, Yang WC. Far-infrared therapy: a novel treatment to improve access blood flow and unassisted patency of arteriovenous fistula in hemodialysis patients. J Am Soc Nephrol. 2007;18:985–992
  23. Stracke S, Konner K, Kostlin I, et al. Increased expression of TGF-beta1 and IGF-I in inflammatory stenotic lesions of hemodialysis fistulas. Kidney Int. 2002;61:1011–1019
  24. Kelly B, Melhem M, Zhang J, et al. Perivascular paclitaxel wraps block arteriovenous graft stenosis in a pig model. Nephrol Dial Transplant. 2006;21:2425–2431
  25. Paulson WD, Kipiani K, Beridze N, DeVita MV, Shenoy S, Iyer SS. Safety and efficacy of locally eluted sirolimus for prolonging AV graft patency (PTFE graft plus Coll-R)—First in man experience. J Am Soc Nephrol. 2008;19:252A
  26. Hoel AW, Conte MS. Edifoligide: a transcription factor decoy to modulate smooth muscle cell proliferation in vein bypass. Cardiovasc Drug Rev. 2007;25:221–234
  27. McAllister TN, Maruszewski M, Garrido SA, et al. Effectiveness of haemodialysis access with an autologous tissue-engineered vascular graft: a multicentre cohort study. Lancet. 2009;373:1440–1446
  28. Ikeno F, Lyons J, Kaneda H, Baluom M, Benet LZ, Rezaee M. Novel percutaneous adventitial drug delivery system for regional vascular treatment. Catheter Cardiovasc Interv. 2004;63:222–230
  29. Kim SJ, Masaki T, Rowley R, Leypoldt JK, Mohammad SF, Cheung AK. Different responses by cultured aortic and venous smooth muscle cells to gamma radiation. Kidney Int. 2005;68:371–377
  30. Sun S, Beitler JJ, Ohki T, et al. Inhibitory effect of brachytherapy on intimal hyperplasia in arteriovenous fistula. J Surg Res. 2003;115:200–208
  31. Misra S, Bonan R, Pflederer T, Roy-Chaudhury P, Bravo I. a pilot study of vascular brachytherapy in polytetrafluoroethylene dialysis access grafts. Kidney Int. 2006;70:2006–2013
  32. Rifkin BS, Brewster UC, Aruny JE, Perazella MA. Percutaneous balloon cryoplasty: a new therapy for rapidly recurrent anastomotic venous stenoses of hemodialysis grafts?. Am J Kidney Dis. 2005;45:e27–e32
  33. Rotmans JI, Heyligers JM, Verhagen HJ, et al. In vivo cell seeding with anti-CD34 antibodies successfully accelerates endothelialization but stimulates intimal hyperplasia in porcine arteriovenous expanded polytetrafluoroethylene grafts. Circulation. 2005;112:12–18
  34. Ikegaya N, Yamamoto T, Takeshita A, et al. Elevated erythropoietin receptor and transforming growth factor-{beta}1 expression in stenotic arteriovenous fistulae used for hemodialysis. J Am Soc Nephrol. 2000;5:928–935
  35. De Marchi S, Falleti E, Giacomello R, et al. Risk factors for vascular disease and arteriovenous fistula dysfunction in hemodialysis patients. J Am Soc Nephrol. 1996;7:1169–1177
  36. Kokubo T, Ishikawa N, Uchida H, et al. CKD accelerates development of neointimal hyperplasia in arteriovenous fistulas. J Am Soc Nephrol. 2009;20:1236–1245
  37. Jin D, Ueda H, Takai S, et al. Effect of chymase inhibition on the arteriovenous fistula stenosis in dogs. J Am Soc Nephrol. 2005;16:1024–1034
  38. Kizu A, Medici D, Kalluri R. Endothelial-mesenchymal transition as a novel mechanism for generating myofibroblasts during diabetic nephropathy. Am J Pathol. 2009;175:1371–1373
  39. Potenta S, Zeisberg E, Kalluri R. The role of endothelial-to-mesenchymal transition in cancer progression. Br J Cancer. 2008;99:1375–1379
  40. Zeisberg EM, Potenta S, Xie L, Zeisberg M, Kalluri R. Discovery of endothelial to mesenchymal transition as a source for carcinoma-associated fibroblasts. Cancer Res. 2007;67:10123–10128
  41. Zeisberg EM, Tarnavski O, Zeisberg M, et al. Endothelial-to-mesenchymal transition contributes to cardiac fibrosis. Nat Med. 2007;13:952–961
  42. Arciniegas E, Carrillo LM, De Sanctis JB, Candelle D. Possible role of NFkappaB in the embryonic vascular remodeling and the endothelial mesenchymal transition process. Cell Adh Migr. 2008;2:17–29
  43. Chang CJ, Chen CC, Hsu LA, et al. Degradation of the internal elastic laminae in vein grafts of rats with aortocaval fistulae: potential impact on graft vasculopathy. Am J Pathol. 2009;174:1837–1846
  44. Burke SKFF, LaRochelle A, Mendenhall HV. Local application of recombinant human type 1 pancreatic elastase (PRT-201) to an arteriovenous fistula (AVF) increases AVF blood flow in a rabbit model. J Am Soc Nephrol. 2008;19:252A
  45. de Graaf R, Kloppenburg G, Tintu A, et al. The new immunosuppressive agent FK778 attenuates neointima formation in an experimental venous bypass graft model. Vascul Pharmacol. 2009;50:83–88
  46. Kloppenburg G, de Graaf R, Grauls G, Bruggeman CA, van Hooff JP, Stassen F. FK778 attenuates cytomegalovirus-enhanced vein graft intimal hyperplasia in a rat model. Intervirology. 2009;52:189–195
  47. Eto Y, Shimokawa H, Hiroki J, et al. Gene transfer of dominant negative Rho kinase suppresses neointimal formation after balloon injury in pigs. Am J Physiol Heart. 2000;278:1744–1750
  48. Matsumoto Y, Uwatoku T, Oi K, et al. Long-term inhibition of rho-kinase suppresses neointimal formation after stent implantation in porcine coronary arteries: involvement of multiple mechanisms. Arterioscler Thromb Vasc Biol. 2004;24:181–186
  49. Sawada N, Itoh H, Ueyama K, et al. Inhibition of rho-associated kinase results in suppression of neointimal formation of balloon-injured arteries. Circulation. 2000;101:2030–2033
  50. Shibata R, Kai H, Seki Y, et al. Role of rho-associated kinase in neointima formation after vascular injury. Circulation. 2001;103:284–289
  51. Lee P-F, Yeh AT, Bayless KJ. Nonlinear optical microscopy reveals invading endothelial cells anisotropically alter three-dimensional collagen matrices. Exp Cell Res. 2009;315:396–410
  52. Liao JKMD, Seto MP, Noma KMDP. Rho kinase (ROCK) inhibitors. J Cardiovasc Pharmacol. 2007;50:17–24
  53. Bone HG, McClung MR, Roux C, et al. Odanacatib, a cathepsin-K inhibitor for osteoporosis: a two-year study in postmenopausal women with low bone density. J Bone Miner Res. 2010;25:937–947
  54. Saegusa K, Ishimaru N, Yanagi K, et al. Cathepsin S inhibitor prevents autoantigen presentation and autoimmunity. J Clin Invest. 2002;110:361–369
  55. Hyun Jung L, Hye Yeong N, Byung Ha L, Dae Joong K, Jai Young K, Jong-sang P. A novel technique for loading of paclitaxel-PLGA nanoparticles onto ePTFE vascular grafts. Biotechnol Prog. 2007;23:693–697
  56. Huynh TN, Chacko BK, Teng X, et al. Effects of venous needle turbulence during ex vivo hemodialysis on endothelial morphology and nitric oxide formation. J Biomech. 2007;40:2158–2166
  57. Begg M, Mo FM, Offertaler L, et al. G Protein-coupled endothelial receptor for atypical cannabinoid ligands modulates a Ca2+-dependent K+ current. J Biol Chem. 2003;278:46188–46194
  58. Rajesh M, Mukhopadhyay P, Batkai S, et al. CB2-receptor stimulation attenuates TNF-{alpha}-induced human endothelial cell activation, transendothelial migration of monocytes, and monocyte-endothelial adhesion. Am J Physiol Heart. 2007;293:H2210–H2218
  59. Yevzlin AS, Guttormsen B, Chan MR, Gimelli G. How I do it: directional atherectomy for in-stent restenosis of a PTFE arteriovenous graft. Semin Dial. 2008;21:266–268

PII: S1931-5244(10)00152-0

doi: 10.1016/j.trsl.2010.07.004

Translational Research
Volume 156, Issue 4 , Pages 216-225 , October 2010

Article Tools

* Image Usage & Resolution